NOVO NORDISK A S · News & developments
Novo Nordisk (NVO) Stock Slides On Dual Trial Cancellations Despite Strong Childhood Obesity Data
Source: foreignpolicyjournal.comBearish
Novo Nordisk cancelled two trials, while the same headline reported strong data in childhood obesity. The headline does not identify the cancelled studies, their development stage or the financial impact.
Why this matters
Trial cancellations can narrow the future product pipeline and reduce the probability-weighted value of research spending. Positive childhood-obesity data may partly offset that risk, but the net effect depends on the commercial potential and costs of both programmes.